Geron (NASDAQ:GERN) Lowered to “Neutral” Rating by B. Riley

B. Riley cut shares of Geron (NASDAQ:GERN) from a buy rating to a neutral rating in a report released on Thursday morning, MarketBeat.com reports. B. Riley currently has $2.00 price target on the biopharmaceutical company’s stock, down from their prior price target of $3.50. B. Riley also issued estimates for Geron’s Q1 2025 earnings at ($0.03) EPS, Q2 2025 earnings at ($0.03) EPS, Q3 2025 earnings at ($0.03) EPS and Q4 2025 earnings at ($0.02) EPS.

Several other equities analysts have also commented on the company. Needham & Company LLC upped their target price on Geron from $6.00 to $7.00 and gave the company a “buy” rating in a report on Monday, January 13th. HC Wainwright cut Geron from a “buy” rating to a “neutral” rating in a report on Wednesday. Finally, Barclays reissued an “overweight” rating and issued a $4.00 price objective (down from $9.00) on shares of Geron in a report on Thursday. One analyst has rated the stock with a sell rating, three have given a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Geron currently has an average rating of “Moderate Buy” and a consensus price target of $5.68.

Geron Trading Up 8.1 %

NASDAQ GERN opened at $1.74 on Thursday. Geron has a one year low of $1.46 and a one year high of $5.34. The company’s 50 day moving average price is $2.97 and its 200 day moving average price is $3.80. The firm has a market capitalization of $1.05 billion, a price-to-earnings ratio of -5.44 and a beta of 0.53. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.74 and a current ratio of 2.89.

Geron (NASDAQ:GERN) last released its quarterly earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.04). Geron had a negative net margin of 682.48% and a negative return on equity of 67.53%. The business had revenue of $47.54 million during the quarter, compared to analyst estimates of $45.29 million. On average, sell-side analysts predict that Geron will post -0.25 EPS for the current year.

Hedge Funds Weigh In On Geron

A number of institutional investors have recently modified their holdings of the stock. RTW Investments LP bought a new position in Geron in the third quarter valued at about $200,268,000. Holocene Advisors LP acquired a new stake in shares of Geron during the third quarter worth $82,498,000. Janus Henderson Group PLC increased its holdings in Geron by 140.0% in the third quarter. Janus Henderson Group PLC now owns 22,565,846 shares of the biopharmaceutical company’s stock valued at $102,193,000 after purchasing an additional 13,163,889 shares during the last quarter. Vestal Point Capital LP lifted its stake in Geron by 947.6% in the fourth quarter. Vestal Point Capital LP now owns 11,000,000 shares of the biopharmaceutical company’s stock valued at $38,940,000 after buying an additional 9,950,000 shares during the period. Finally, Braidwell LP bought a new position in Geron during the fourth quarter worth about $24,802,000. 73.71% of the stock is owned by institutional investors.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.